
The US Food and Drug Administration (FDA) has approved another combination treatment involving Darzalex.
The drug has now been approved in the US in combination with Carfilzomib and Dexamethazone as a treatment for adult patients with recurring multiple myeloma, a type of bone marrow cancer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app